Clinuvel Pharmaceuticals Ltd (CUV) — Cash Flow Quality Index
Clinuvel Pharmaceuticals Ltd (CUV) has a Cash Flow Quality Index of 1.20x as of December 2025. Operating cash flow of AU$12.52 Million exceeds net income of AU$10.44 Million, indicating high earnings quality where cash backs reported profits. Explore Clinuvel Pharmaceuticals Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Clinuvel Pharmaceuticals Ltd Cash Flow Quality Index (2017–2025)
Historical Cash Flow Quality Index for Clinuvel Pharmaceuticals Ltd across 9 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check CUV tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Clinuvel Pharmaceuticals Ltd (2017–2025)
Year-by-year earnings quality comparison for Clinuvel Pharmaceuticals Ltd. For live market cap and the full company financial profile, see Clinuvel Pharmaceuticals Ltd stock valuation.
| Year | Quality Index | Operating CF (AUD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.14x | AU$41.10 Million | AU$36.17 Million | ▲ +9.3% |
| 2024 | 1.04x | AU$37.05 Million | AU$35.64 Million | ▼ -13.8% |
| 2023 | 1.21x | AU$36.91 Million | AU$30.60 Million | ▼ -36.8% |
| 2022 | 1.91x | AU$39.87 Million | AU$20.88 Million | ▲ +145.2% |
| 2021 | 0.78x | AU$19.26 Million | AU$24.73 Million | ▼ -17.4% |
| 2020 | 0.94x | AU$14.19 Million | AU$15.05 Million | ▼ -7.4% |
| 2019 | 1.02x | AU$18.46 Million | AU$18.13 Million | ▲ +15.1% |
| 2018 | 0.88x | AU$11.69 Million | AU$13.22 Million | ▼ -36.0% |
| 2017 | 1.38x | AU$9.92 Million | AU$7.18 Million | — |